Lacunar Intervention Trial 1 (LACI-1)

Stroke Clinical Trial

— Prevent-SVD  

Official title:

Preventing Cognitive Decline and Dementia From Cerebral Small Vessel Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02481323
• Other study ID #: PrevSVD-2015
• Secondary ID: 2015-001953-3325
• Status: Completed
• Phase: Phase 2
• First received: June 19, 2015
• Last updated: January 18, 2018
• Start date: March 2016
• Est. completion date: November 30, 2017

Study information

• Verified date: January 2018
• Source: University of Edinburgh
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Phase II pilot randomised, factorial, short term dose escalation, open label, blinded intermediary endpoint trial, in two hospital centres in the UK, of tolerability and safety of cilostazol, isosorbide mononitrate, both or neither in patients with small vessel disease manifest as symptomatic small subcortical stroke.

Description:

A quarter of all ischaemic strokes are lacunar (small vessel) in type, about 35000 per annum in the United Kingdom, and due to an intrinsic, non-atheromatous, non-cardioembolic perforating cerebral arteriolar disease. 'Small vessel disease' also affects the brain diffusely, causing up to 40% of dementias, alone or mixed with Alzheimer's disease, 350,000+ patients estimated currently in the United Kingdom. There is no proven treatment: conventional antiplatelet drugs may be ineffective or even hazardous, antihypertensive treatment and statins have been disappointing. The disease mechanism is poorly understood but endothelial dysfunction, blood-brain barrier failure and vessel stiffness appear to contribute to the pathogenesis. Promising data available for licensed drugs with relevant modes of action, cilostazol (>6000 stroke patients in the Asia Pacific region) and isosorbide mononitrate (ISMN, widely used in cardiac disease) support their testing in small vessel disease. This trial will be a phase 2, randomised, dose-escalation, factorial trial to test short-term administration of cilostazol, Isosorbide Mononitrate, both, or neither, to provide data on patient tolerability of dose (including headache, dizziness), safety (including blood pressure, platelet function), provide mechanistic evidence of efficacy (cerebrovascular reactivity, arterial compliance), and to inform the design of a larger phase 2-3 trial. The trial will recruit 60 patients with small vessel disease, in two expert stroke centres (Edinburgh and Nottingham) where there are suitable patients, expert stroke centres, established trials infrastructures and neuroimaging and platelet testing expertise. The trial will also advance methods to stratify patients by small vessel disease burden in routine practise and data on intermediary mechanistic outcomes to assist in planning future trials testing novel agents for either stroke or dementia.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 57
• Est. completion date: November 30, 2017
• Est. primary completion date: August 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 35 Years and older

Eligibility

Inclusion Criteria:

• Mild symptomatic ischaemic stroke in the past four years compatible with a clinical lacunar stroke syndrome, with brain magnetic resonance imaging or computed tomography scanning that is compatible with a symptomatic small subcortical (lacunar) infarct, or if no recent relevant infarct is visible, that excluded other cause for symptoms

• Age > 35 years

• Independent in activities of daily living (modified Rankin =2)

• Able to give consent themselves

Exclusion Criteria:

• Other significant active neurological illness present since suffering stroke (eg seizures, multiple sclerosis, brain tumour)

• Age < 35

• Montreal Cognitive Assessment score <26

• Requiring assistance with activities of daily living (Modified Rankin =3)

• Active cardiac disease (atrial fibrillation, myocardial infarction in past 6 months, active angina, symptomatic cardiac failure)

• Carotid stenosis > 50% in the symptomatic artery territory requiring carotid endarterectomy (prior and apparently successful carotid endarterectomy is not an exclusion criterion)

• Definite indication for, or definite contraindication to either trial drug

• Unable to swallow

• Bleeding tendency (platelets<100, taking anticoagulant medication)

• Unlikely to comply with trial medication

• Planned surgery during the trial period

• History of intracranial haemorrhage (subdural haematoma, subarachnoid haemorrhage, intracerebral haemorrhage, but not asymptomatic haemorrhagic transformation of infarction)

• Other life threatening illness

• History of drug overdose or attempted suicide or significant active mental illness

• Pregnancy

• If recruited in Edinburgh and participating in cerebrovascular reactivity arm of trial: active respiratory illness (such as moderate to severe asthma or chronic obstructive airways disease), unable to tolerate magnetic resonance imaging or unable to lie flat

Related Conditions & MeSH terms

• Cerebral Small Vessel Diseases
• Cognitive Dysfunction
• Cognitive Impairment
• Stroke

Intervention

Drug:
• isosorbide mononitrate
slow release nitric oxide donor that enhances vasodilation and widely used in angina prophyaxis
• cilostazol
phosphodiesterase 3-inhibitor that enhances vessel wall function with weak antiplatelet effects

Locations

Country	Name	City	State
United Kingdom	University of Edinburgh	Edinburgh
United Kingdom	University of Nottingham	Nottingham

Sponsors (2)

Lead Sponsor	Collaborator
University of Edinburgh	University of Nottingham

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Tolerability proportion of patients able to tolerate the target dose	proportion of patients able to tolerate the target dose	8 weeks
Secondary	Safety - bleeding	systemic or intracranial bleeding	12 weeks
Secondary	Safety - recurrent stroke	recurrent vascular events,	12 weeks
Secondary	Safety - death	death	12 weeks
Secondary	Safety - blood pressure	reduction in blood pressure	8 weeks
Secondary	Safety - bleeding	effect on platelet function assessed using p-selectin	8 weeks
Secondary	Efficacy - cerebrovascular function	effect on cerebrovascular reactivity assessed using carbon dioxide challenge in magnetic resonance imaging	8 weeks
Secondary	Efficacy - systemic arterial stiffness	effect on systemic large artery stiffness assessed with pulse wave velocity measurement	8 weeks
Secondary	Tolerability Proportion of patients with headache that interferes with daily activities	Proportion of patients with headache that interferes with daily activities	8 weeks
Secondary	Tolerability Proportion of patients with dizziness that interferes with daily activities	Proportion of patients with dizziness that interferes with daily activities	8 weeks
Secondary	Tolerability Proportion of patients with nausea that interferes with daily activities	Proportion of patients with nausea that interferes with daily activities	8 weeks
Secondary	Tolerability Proportion of patients with palpitations	Proportion of patients with palpitations	8 weeks
Secondary	Tolerability Proportion of patients with loose stools	Proportion of patients with loose stools	8 weeks
Secondary	Tolerability Tablet count	Tablet count	8 weeks